Taiwan Liposome Company, Ltd. - ADRs (TLC) News
Filter TLC News Items
TLC News Results
|Loading, please wait...|
TLC News Highlights
- For TLC, its 30 day story count is now at 2.
- Over the past 27 days, the trend for TLC's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about TLC are SAL.
Latest TLC News From Around the Web
Below are the latest news stories about Taiwan Liposome Company Ltd that investors may wish to consider to help them evaluate TLC as an investment opportunity.
TLC Announces Voluntary Delisting and Deregistration of American Depositary Shares
This communication does not constitute an offer of any securities for sale or subscription or a solicitation of an offer to purchase or subscribe to any securities in any jurisdiction. The securities to be issued pursuant to the stock swap transaction will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), or under any relevant securities laws of any state or other jurisdiction of the United States. Such securities will be issued in reliance upon the exem
TLC Reports Second Quarter 2021 Financial Results and Provides Business Update
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Aug. 12, 2021 (GLOBE NEWSWIRE) -- TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced financial results for the second quarter ended June 30, 2021 and provided a business update. “The second quarter of 2021 was marked mainly by the timely approval of our liposomal amphotericin B product in India and the immediate partnerships for their commercialization and sal
Ropivacaine Market 2021 SWOT Analysis, Competitive Landscape and Significant Growth | Top Brands:AstraZeneca, PainReform Ltd, Taiwan Liposome Company, Aspen Pharmacare, Encore Therapeutics, Celgene
This report studies the Ropivacaine Market with many aspects of the industry such as market size, market status, market trends and forecast. The report also provides brief information on competitors and opportunities for specific growth with the key market drivers. Find the comprehensive analysis of the Ropivacaine market segmented by company, region, type and applications 
Global Thymic Carcinoma Treatment Market 2021 Future Set to Massive Growth with High CAGR value | Market Players: Merck & Co., Inc., Sumitomo Dainippon Pharma Co., Ltd., Novartis AG, Onxeo SA, Tiziana Life Sciences Plc, Taiwan Liposome Company, Ltd.
The report on Global Thymic Carcinoma Treatment Market has been provided by researchers for a detailed understanding of market performance over an estimated period of time set from 2021 to 2026. However, this report has introduced a brief overview to provide the reader with better information on this report. This brief description contains a basic 
Short Squeeze Stocks: XELA, NEGG and 3 Other Stocks Experts Think Are Ready to Pop
Looking for the next AMC, retail investors are on the hunt for the next squeeze.
TLC Announces Details of Stock Swap Transactions
TAIPEI, Taiwan, July 05, 2021 (GLOBE NEWSWIRE) -- Taiwan Liposome Company (Nasdaq: TLC, TWO: 4152, the company), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced details of the companys board-approved stock swap transactions with Woods Investment Company, Ltd. (Woods) at a press conference held at 4:00pm Taipei time at the Taipei Exchange (TPEx). Details of the stock swap transactions are as follows:
Taiwan Liposome Company, Ltd. Unsponsored ADR (TLC) Soars 30.3%: Is Further Upside Left in the Stock?
Analysts Offer Insights on Healthcare Companies: NuVasive (NUVA), Crinetics Pharmaceuticals (CRNX) and Taiwan Liposome Company (TLC)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on NuVasive (NUVA), Crinetics Pharmaceuticals (CRNX) and The post Analysts Offer Insights on Healthcare Companies: NuVasive (NUVA), Crinetics Pharmaceuticals (CRNX) and Taiwan Liposome Company (TLC) appeared first on Smarter Analyst .
Taiwan Liposome''s Inhalable Liposome Formulations of Antiviral Drugs Show Promise In COVID-19
InspirMed Inc presented data on the potential advantages of inhalable liposome formulations of antiviral drugs at the International Society for Aerosols in Medicine Congress. InspirMed is a subsidiary of Taiwan Liposome Company (NASDAQ: TLC ), specializing in developing inhalable liposome formulation programs for severe acute and chronic pulmonary diseases. Pharmacokinetic studies on inhalable liposomal GS-441524 (ISPM21) and inhalable liposomal hydroxychloroquine Full story available on Benzinga.com
TLC to Present at Upcoming Virtual Investor Conferences
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, March 02, 2021 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced that the Company’s management team will be presenting at the following virtual investor conferences: HC Wainwright & Co Global Life Sciences Conference (March 9-10, 2021)Presentation: on-demand starting 7am ET, Tuesday, March 9, 2021 Oppenheimer 31st Annual Healthcare Conference (March 16-17, 2021)Presentation: 8am ET, Wednesday, March 17, 2021 The management team will also be participating in one-on-one meetings during the conference. The corporate presentation will be available on the TLC website at www.tlcbio.com in the Investors section, ...